nVerses Capital’s Esperion Therapeutics ESPR Stock Holding History

nVerses Capital’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-19,453	Closed	-$61.5K	–	84
2026 Q2	$61.5K	Buy	+19,453	New	+$54.4K	0.09%	263
2026 Q1	–	Sell	-67,450	Closed	-$250K	–	396
2025 Q4	$250K	Buy	+67,450	New	+$218K	0.56%	85

Other funds holding ESPR

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

nVerses Capital's ESPR Position: Q3 2026 in Review

nVerses Capital sold out of Esperion Therapeutics (ESPR) in Q3 2026, closing a stake of 19,453 shares — an estimated $61.5K sold.

nVerses Capital first reported a position in ESPR in Q4 2025 and held it in 2 quarters. The position peaked at $250K in Q4 2025. 2 funds tracked by Wall St. Rank hold ESPR as of Q3 2026.

nVerses Capital reported no remaining Esperion Therapeutics position as of Q3 2026 after selling out during the quarter.
nVerses Capital sold 19,453 Esperion Therapeutics shares in Q3 2026, an estimated $61.5K.
nVerses Capital first reported a position in Esperion Therapeutics in Q4 2025 and held it in 2 quarters.
nVerses Capital's Esperion Therapeutics position peaked at $250K in Q4 2025.
2 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2026.

Based on nVerses Capital's 13F filing for Q3 2026.